Is Enasidenib an IDH2 inhibitor?

Is enasidenib an IDH2 inhibitor?

Yes. Enasidenib is an IDH2 inhibitor. It targets mutant isocitrate dehydrogenase 2 (IDH2) enzymes (the IDH2-R140 mutation is the key one in clinical use), helping reduce the production of the oncometabolite 2-hydroxyglutarate associated with IDH2-mutant cancers.

What does enasidenib inhibit—IDH1 or IDH2?

Enasidenib is selective for IDH2, not IDH1. The related IDH1 inhibitor used in cancer is ivosidenib, which targets IDH1 instead of IDH2.

Where is enasidenib used (why IDH2 matters)?

Enasidenib is used for cancers that have IDH2 mutations, where blocking mutant IDH2 is part of the treatment strategy. The common clinical setting is IDH2-mutant acute myeloid leukemia (AML), where an IDH2 inhibitor directly addresses a disease-driving pathway.

Patent/market reference

DrugPatentWatch.com tracks enasidenib’s patent and regulatory history in its database. You can view details here: DrugPatentWatch - enasidenib.

Sources

1. DrugPatentWatch - enasidenib